Penthrane
(Methoxyflurane)Phase 3Small molecule
Methoxyflurane is an inhaled anesthetic gas used to put patients to sleep during surgery and other medical procedures. It can also be used in low doses for pain relief in emergency situations.[1] Penthrane is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]
Penthrane is one of 65 small molecule programs targeting Fever. It is currently in Phase 3.
6
Indications
20
Total Trials
4
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
75 competitors in Acute Myocardial Infarction
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Bayer Aspirin
BayerApproved
Zebeta
TevaApproved
Radicava
ShionogiApproved
Praluent
RegeneronApproved
Onglyza
AstraZenecaApproved
Neoral
NovartisApproved
Angiomax
BBaxter Healthcare Corporation
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Zetia
OOrganon and Co
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Analgesia3 trials
Efficacy and Safety2 trials
Pain Management2 trials
Intravenous1 trial
11 more indications
Acute Myocardial Infarction1 trial
Local Anesthetic1 trial
Local1 trial
Pain Control1 trial
BPH1 trial
Treatment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Methoxyflurane. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- GABA-a Receptor; Anion Channel Positive Modulator; Glycine Receptor (alpha-1/beta) Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPurdue Pharma, Canada